Harvard Medical School is accelerating therapeutic discovery and advancing bold approaches to some of humanity’s most urgent biomedical challenges through a landmark $200 million commitment from Len Blavatnik and the Blavatnik Family Foundation. In recognition of this transformative gift, HMS established the Blavatnik Institute, an umbrella research institute that brings together the School’s 11 basic and social science departments. By uniting this breadth of expertise, the Institute advances HMS’s mission to transform health through curiosity-driven research that stimulates the development of new therapies and tools to diagnose and prevent disease.
Building on this investment, Len Blavatnik and the Blavatnik Family Foundation committed an additional $18.86 million in 2025 to:
- Extend support for the Blavatnik Therapeutics Challenge Awards, an annual awards program that advances promising discovery science at HMS toward the creation of new medicines that could be life-changing for patients.
- Establish the Blavatnik Institute Early Career Investigator Awards, which are designed to fuel high-potential fundamental and translational research conducted by exceptional junior faculty members on the HMS Quadrangle within the first decade of their careers as principal investigators.
- Create the Blavatnik Postdoctoral Fellowship Fund, which will support scientists from Israel as they conduct research at HMS over four years, investing in promising researchers at a pivotal stage of their scientific careers.
Together, these commitments will support exceptional scientists, strengthen fundamental and translational research, and advance promising discoveries toward new tools, technologies, and therapies that improve human health.
